Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2

Conditions

Recurrence 2Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell 1Lymphoma 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 100Rituximab 82fludarabine phosphate 46Peripheral Blood Stem Cell Transplantation 45fludarabine 43Lenalidomide 35Filgrastim 33Methotrexate 32Cytarabine 32Busulfan 32venetoclax 31Etoposide 31Cyclosporine 30Dexamethasone 29Radiotherapy 28Mycophenolic Acid 28Melphalan 28Bendamustine Hydrochloride 25Antilymphocyte Serum 25Vincristine 24Gemcitabine 24ibrutinib 22Whole-Body Irradiation 22Doxorubicin 20Tacrolimus 19Methylprednisolone 18Bortezomib 18Brentuximab Vedotin 16pembrolizumab 15Prednisone 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Immunoconjugates × Lymphoid × Clear all
NCT06796517 2025-01-28

Immunotherapy in Lymphoma

Seoul St. Mary's Hospital

Recruiting
72 enrolled
Lymphoid

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell

NCT01841021 2017-01-19

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Terminated
1 enrolled 5 charts
Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡